Sobi has Entered Into Agreement to Sell Priority Review Voucher
- Thursday, August 22, 2019, 1:15
- Finance
- Add a comment
STOCKHOLM, Aug. 22, 2019 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has entered into an agreement to sell a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) to AstraZeneca for a total cash consideration of USD 95 M. A PRV entitles the holder…
Source: https://www.prnewswire.com:443/news-releases/sobi-has-entered-into-agreement-to-sell-priority-review-voucher-300905675.html
About the Author
adminasapcorp has written 38955 stories on this site.